Practice for preterm patent ductus arteriosus; focusing on the hemodynamic significance and the impact on the neonatal outcomes
- Author:
Jin A LEE
1
Author Information
- Publication Type:Review
- Keywords: Patent ductus arteriosus; Premature infant; Therapeutics; Treatment outcome
- MeSH: Biomarkers; Bronchopulmonary Dysplasia; Comorbidity; Consensus; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; Hemodynamics; Hemorrhage; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Very Low Birth Weight; Mortality; Risk Factors; Spectroscopy, Near-Infrared; Treatment Outcome; Uncertainty
- From:Korean Journal of Pediatrics 2019;62(7):245-251
- CountryRepublic of Korea
- Language:English
- Abstract: Hemodynamically significant preterm patent ductus arteriosus (PDA) affects mortality; comorbidities such as necrotizing enterocolitis, intraventricular hemorrhage, and bronchopulmonary dysplasia; and adverse long-term neurodevelopmental outcomes in preterm infants, particularly in very low birth weight infants. However, recent studies have indicated that there is no consensus on the causal relationship between PDA and neonatal outcomes, the benefit of PDA treatment, the factors guiding the need for treatment, and optimal treatment strategies. Such uncertainty has resulted in wide variations in practice for treating preterm PDA between units, regions, and nations. Nowadays, there has been a paradigm shift to more conservative treatment for preterm PDA, and suggestions regarding selective management of preterm PDA considering risk factors and hemodynamic significance are increasing. Neonatologist-performed echocardiography and advances in modalities to assess hemodynamic significance such as biologic markers and near-infrared spectroscopy also help improve the efficacy of selective treatment of preterm PDA.
